Weiss Ratings Reaffirms Hold (C) Rating for Genmab A/S (NASDAQ:GMAB)

Genmab A/S (NASDAQ:GMAB - Get Free Report)'s stock had its "hold (c)" rating restated by research analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

Several other equities research analysts have also recently commented on GMAB. HC Wainwright increased their price target on Genmab A/S from $36.00 to $40.00 and gave the company a "buy" rating in a report on Thursday, October 2nd. Guggenheim upgraded Genmab A/S from a "neutral" rating to a "buy" rating and set a $43.00 price target for the company in a research report on Tuesday, September 23rd. Truist Financial raised their price target on Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a research report on Tuesday, July 8th. Wall Street Zen upgraded Genmab A/S from a "buy" rating to a "strong-buy" rating in a research note on Friday, September 26th. Finally, Zacks Research upgraded Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, October 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $40.80.

Genmab A/S Price Performance

Shares of Genmab A/S stock opened at $32.74 on Wednesday. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $33.63. The stock has a market capitalization of $21.02 billion, a P/E ratio of 16.45, a PEG ratio of 1.84 and a beta of 0.98. The business has a 50 day simple moving average of $26.46 and a two-hundred day simple moving average of $22.69.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.39 by $0.15. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.The firm had revenue of $925.00 million during the quarter, compared to analysts' expectations of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Genmab A/S will post 1.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

A number of institutional investors have recently added to or reduced their stakes in GMAB. Headlands Technologies LLC lifted its position in shares of Genmab A/S by 1,525.0% during the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock valued at $31,000 after acquiring an additional 1,464 shares during the period. Osaic Holdings Inc. raised its position in shares of Genmab A/S by 37.8% during the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company's stock worth $33,000 after purchasing an additional 440 shares during the last quarter. CWM LLC raised its position in shares of Genmab A/S by 50.5% during the 2nd quarter. CWM LLC now owns 1,797 shares of the company's stock worth $37,000 after purchasing an additional 603 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its position in shares of Genmab A/S by 124.3% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock worth $38,000 after purchasing an additional 1,070 shares during the last quarter. Finally, AlphaCore Capital LLC acquired a new position in shares of Genmab A/S during the 2nd quarter worth approximately $44,000. Hedge funds and other institutional investors own 7.07% of the company's stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.